The following lines will be focus on the Acomplia and other weight loss related news. One of the world top pharmaceutical and health care research firms is Decision Resources and they say that obesity has taken the proportions of an epidemic in the United States, Spain, Japan, Italy, Great Britain, Germany and France, which are the major world markets. The sales of the treatment associated with the weight loss in the 2006 were somewhere between the 478 million and 2.7 billion dollars, but the Decision Research state that his market will increase five times until the year 2016. According to this company, USA will be the state with the biggest demand of such products. But the FDA was not so lean on the Acomplia and they requested a lot of evidence associated with the safety of this medicine. Due to this, the medications were withdrawn but the next year they will be submitted again. This may hamper the coming of the new generation of medicines in this area, such as Pfizer, Merck, Arena Pharmaceuticals and Amylin, which develop the anti-obesity medications.
There are two options connected with the new medications and those are less convenient delivery method via injections or the same method of production like the Acomplia. But the medicines that are made in the same way like the Acomplia will come across the same problems with safety regulations as well. However, do not think that this kind of medications will come in the market in the next eight years.
The health insurers and self-regulating doctor body, called G-BA, classified this medication as lifestyle drug and this was later confirmed by the Berlin social court. The non-therapeutic expenditure is not allowed to be reimbursed by the health insurance companies according to the German law. People think that obesity is a result of a lifestyle and cannot be treated as an illness. Also, due to the costs of the medications, those who are mostly stricken by this problem, the lower class, cannot afford it, so it is only reserved for the middle and the upper class of people. Liver disease will be brought by the alcoholic fatty liver and this may be prevented by the Acomplia. This was detected during the researches on mice, which exhibited no fatty liver alcoholic effects. So with some lifestyle alterations and the use of Acomplia, fatty deposits can be prevented along with the further complications. But this will have to be confirmed by the full clinical trials.